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Detection of HIV-1-Infected Cells From Patients
Using Nonisotopic In Situ Hybridization
By Robert H. Singer, Kevin S. Byron, Jeanne B. Lawrence, and John L. Sullivan
We have demonstrated that a sensitive. nonisotopic in situ
hybridization (ISH) assay can be used to detect HIV-
infected cells from seropositive, asymptomatic individuals.
Our assay is based on the detection of a biotinated HIV
DNA probe hybridized to human immunodeficiency virus
(HIV)-infected peripheral blood lymphocytes (PBL) using
streptavidin and alkaline phosphatase to identify positive
cells. This assay is rapid in that it can be performed within a
day and is sensitive enough to unambiguously identify a
rare, single, positive cell. Patient samples derived from
HIV-seropositive hemophiliacs and HIV-seropositive in-
fants were analyzed before and after coculture with normal
PBL. The same samples were investigated using a Dupont
CQUIRED immunodeficiency syndrome (AIDS) has
affected over 60,000 individuals in the United States
over the past 10 years with a mortality rate of approximately
60%.’ Based on surveys of seroprevalence, it has been
estimated that 1 million to I .5 million Americans have been
infected with the human immunodeficiency virus type I
(HIV l).2 Little information is currently available regarding
the direct detection and quantitation of HIV infection in
vivo. It is known that blood, semen, and vaginal secretions
harbor HIV and represent the sources ofspread of HIV from
infected to noninfected individuals. Once HIV enters the
host, the virus infects and replicates in a variety of cells,
including blood and tissue monocytes/macrophages and
I-helper (CD4) lymphocytes.3 Viral replication precedes the
production of antibody by the host and may occur in the
absence of symptoms. The recent studies of Ward et a14
suggest that as many as 460 individuals/year are infected
with HIV because of HIV-contaminated blood products.
These HIV-infected blood products are obtained from sero-
negative donors who are thought to be acutely HIV infected
and viremic prior to the appearance of HIV antibody. While
the risk ofacquiring HIV infection through blood transfusion
remains low (1 in 40,000), it is probable that continual
spread in the heterosexual community will result in more
blood donors being in the “window period” of HIV infection.
The development of a rapid, sensitive, and convenient nonra-
dioisotopic in situ hybridization assay to detect the viral
genome directly in infected cells would increase the likeli-
hood of detecting all HIV-infected individuals prior to the
generation of a virus-specific immune response. A method to
detect HIV directly would also be extremely useful in those
situations when antibodies are not informative (eg, in infants
of HIV-seropositive mothers where passively acquired
maternal antibodies obscure the diagnosis5 and in those
l-IIV-infected individuals who fail to mount an appropriate
antibody response6 or lose the ability to maintain HIV-
specific antibody following acute infection.7 Finally, a sensi-
tive and quantitative method ofdetecting HIV-infected cells
would be helpful in assessing the natural history of infection
and in monitoring antiviral therapy or vaccine development.
In situ hybridization offers distinct advantages over
immunlogic methods, since it is able to detect infected cells
whether or not viral proteins are expressed. Such hybridiza-
P24 antigen-capture kit. It was found that ISH always
detected the same positive samples as antigen capture.
often in shorter times of coculture. In situ hybridization
detected over half of our HIV-infected hemophilia patient
population as virus positive. whereas the antigen capture
assay detected less than one fourth as virus positive. In situ
hybridization detected positive cells directly, without
coculture, in 1 2 out of 35 (34%) hemophiliacs and in three
out of eight (37%) infants. The speed, sensitivity, and
confidence of ISH and nonisotopic detection indicates that
it will be useful as a tool for clinical research and
diagnosis.
a 1989 by Grune & Stratton, Inc.
tion was first used to detect HIV-infected cells in frozen
brain tissue obtained from AIDS patients.8 Harper et al9
have published a further report demonstrating the detection
of HIV-infected cells in the lymph nodes and peripheral
blood of individuals with AIDS and AIDS-related complex
(ARC) by in situ hybridization. Bush et al’#{176}have shown that
in situ hybridization can be used to detect virus-positive cells
in cocultures of peripheral blood mononuclear cells from
symptomatic patients at an earlier time of culture compared
to any other viral detection technique. In these reports the in
situ hybridization methodology” employed a radioisotopi-
cally (355) labeled probe. This report improves and applies
nonisotopic in situ hybridization (ISH) to the detection of
HIV-infected cells.
METHODS
Preparation of peripheral-blood lymphocytes and cocul-
ture. Blood was obtained by venous puncture and the lymphocytes
separated by Ficoll-Hypaque (FH) centrifugation. Peripheral blood
mononuclear cells were isolated from seronegative and seropositive
individuals (3 x 106 cells) and cocultured with cells (3 x 106) from
healthy seronegative donors that had been stimulated for 3 to 4 days
with phytohemagglutinin (PHA) (2 .tg/mL, Wellcome Diagnostics,
Research Triangle Park, NC). Cocultured cells were maintained in
HEPES-buffered RPMI 1640 supplemented with 20% fetal calf
serum (FCS), 2 zg/mL polybrene (Sigma Diagnostics, St Louis,
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MO), 10% interleukin-2 (IL-2, Cellular Products Inc. Buffalo, NY),
and 12.5 g/mL gentamicin (GIBCO, Grand Island, NY) for 3
weeks. Cultures were split twice weekly and were supplemented with
fresh PHA-stimulated normal mononuclear cells at 7-day intervals.
Immunofluorescence. Cells were mixed with a 1: 100 dilution of
patient serum (from a HIV-seropositive individual) in phosphate-
buffered saline (PBS) and, after a series of washes in PBS, were
detected with fluorescein-conjugated rabbit antihuman IgG (Cappel
Laboratories, Organon Teknika, West Chester, PA). Cells were
visualized under epifluorescence optics at 40 X objective.
Dot blot. Cellular pellets (2 x 106 cells) were washed and
extracted three times with phenol chloroform after sodium dodecyl
sulfate (SDS) (1%) treatment of the cells. Isolated nucleic acids
were purified by ethanol precipitation, resuspended in high salt (0.3
mol/L Na acetate), and blotted onto nitrocellulose filters. Filters
were hybridized with 32P-labeled HIV genomic probe’2 (3 x 108
cpm/tg) overnight, washed, and exposed for 72 hours to radio-
graphic film with intensifying screens.
Probe preparation by nick translation. An amount of 1 .5 ML of
400 mol/L biotin dUTP’3 (BRL, Gaithersburg, MD) or the
corresponding dATG mix for radioactive probes (or for radioactive
probes, 355-dCTP, Amersham 1,000 Ci/mmol/L, diluted 1:3 with
unlabeled dCTP and used at a final concentration of 6 imol/L), I
tL of dACG mix (dATP, dCTP, dGTP 600 mol/L each, PL
Biochemicals, St Louis, MO), or dAGT mix for radioactive probes, 1
sL of lOX nick translation buffer (0.5 mol/L Tris Cl, pH 7.2; 0.1
mmol/L Mg504; I mmol/L dithiothreitol), 500 sg/mL bovine
serum albumin (BSA, Pentax Frac V) 5-sL sterile glass distilled
H20; 1 &Lof0.l g/tL HIV DNA (pJM [HIV-118.9[121 contain-
ing 8.9 kb of HIV-1 DNA), I L of DNase (final 34 ng/mL:
concentration determines the probe size; large probe sizes cause
background), I zL of DNA Polymerase I (Boehringer). Incubation
is 3 hours at I 5#{176}C,then 90 zL of 50 mmol/L EDTA and I L of 10%
SDS is added. Purification from incorporated nucleotides is with a
sterile G50 sephadex “spin” column packed in a 1 mL disposable
syringe.
In situ hybridization. The schematic in Fig I outlines the
following methodology. Cells were washed in PBS, and 25 x iO
cells in 25 zL were applied to each well of a multiwell serologic slide
(Celline, 5-mm wells). The excess fluid was immediately withdrawn
by the pipette, leaving cells to be air dried (10 minutes), fixed in 4%
paraformaldehyde in PBS (5 minutes), and stored in 70% ethanol at
4#{176}C.From 1% to 4% (25,000 to 100,000; median 50,000) of the cells
applied actually remain adhered to the slide. At appropriate times,
slides stored in 70% alcohol are rehydrated in a 10-minute PBS, 5
mmol/L MgCI bath, then 10 minutes in 0.5% triton/0.5% saponin
solution, washed in 2X SSC, treated for 10 minutes in 0.1 mol/L
triethanolamine and 0.25% acetic anhydride, washed again in 2X
SSC, and incubated for 2 minutes at 70#{176}Cin 70% formamide in 2X
SSC before plunging into 70% ethanol and dehydrating through
graded ethanol and air drying. This makes viral DNA as well as
RNA accessible for hybridization. While the cells can be hybridized
directly out of the 70% ethanol after rehydration in PBS, for a
shorter pretreatment protocol, the signal is diminished. Forty nano-
grams of probe DNA is used, which can be obtained by aliquoting 40
iL of nick-translated probe into a microfuge tube and lyophilizing it
with 4 tL of carrier nucleic acids (10 mg/mL of sheared salmon
sperm and tRNA). Five microliters ofdeionized formamide is mixed
with the lypholite and placed in a 90#{176}Cheating block for 10 minutes.
Hybridization buffer is prepared by mixing 30 pL 20X SSC; 30 ML
BSA, 60 ILL dextran sulfate (50% solution, autoclaved in water) and
30 ML H2O. Slides are then quickly used with the deposition of 5 ML
of the heated probe mixed rapidly with an equal amount of hybrid-
ization buffer onto each serologic well (10 ML total), covered with a
small strip of parafilm, and placed for 3 hours (or overnight as is
LYMPHOCYTES
ON SLIDE
BIOTINATED VIRAL
COMPLEMENTARY
DNA PROBE PUT ONTO
CELLS
PROBE HYBRIDIZES
TO VIRAL NUCLEIC
ACIDS IN CELL
AVIDIN CONJUGATED TO
ALKALINE PHOSPHATASE
BINDS TO BIOTIN ON PROBE
ENZYME - DEPENDENT
COLOR GENERATING SYSTEM
Fig 1 . Schematic of the nonisotopic in situ hybridization and
detection protocol.
convenient) in a humidified 37#{176}Cincubator. Slides are rinsed in 50%
formamide in 2X SSC for 30 minutes at 37#{176}C,then placed in 2X
SSC for 30 minutes and finally in 1X SSC for 30 minutes.
Probes obtained from Molecular Biosystems, Inc (Dupont SNAP
probe, San Diego, CA) were used at a concentration of 1 ng per
hybridization (6 nmol/L concentration). Cells were hybridized in
5x SSC, 0.5% SDS, and 1% BSA at 50#{176}Cfor 20 minutes in a
humidified environment. Samples were then washed at 42#{176}Cfor 5
minutes in I X SSC at room temperature for 5 minutes each. The
detection of the alkaline phosphatase was as described below.
Detection ofbiotinated probes. Originally streptavidin followed
by biotinated alkaline phosphatase after the method ofSinger et al’4
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Table 1 . Detection of HIV-Infected Cells From Seropositive and
Seronegative Individuals: Comparison of Antigen-Capture ELISA
With In Situ Hybridization
In Situ
p24 Antigen Capture Hybridization
Patient Population (N) Positive (%) Positive (%)
Coculture
Seronegative hemophiliacs (2) 0 0
Seropositive hemophiliacs (34) 8 (24%) 18 (54%)
Seronegative normal controls (8) 0 0
Seropositive infants (1 5) 5 (33%) 8 (53%)
Direct detection’
Seronegative normal controls (7) 0 0
Seropositive hemophiliacs (35) 4 ( 1 1 %) 1 2 (34%)
Seropositive infants (8) 2 (25%)t 3 (37%)
‘At four intervals over 2 1 dayS, the culture was tested, and the
sample was considered positive if any one of those days was positive. For
in situ hybridization, 1 cell per well (average 50,000 cells) was sufficient
for a positive determination. For the P24 antigen capture ELISA, the
samples were assayed as described by Dupont: 200 z1 of supernatant
was tested, and readings corresponding to 40 pg/mL of p24 antigen or
greater were considered positive. For direct detection, patient mononu-
clear cells were put directly on slides and processed as described
previously. Serum samples were tested for the presence of p24 antigen
on each patient studied by direct detection.
tBoth infants with detectable serum p24 antigen had symptomatic
HIV infection, one each with AIDS and progressive generalized lymphade-
nopathy.
was used for the data presented in Figs 2 and 3. The clinical results
reported in Table I were obtained using streptavidin-alkaline phos-
phatase conjugate (Dakopatts, Santa Barbara, CA), which removes
a step in the detection protocol and improves the background. The
conjugate is used after dilution 1:250 into 4X SSC with 1% BSA and
exposed to the hybridized cells for 30 minutes. After washing in 4X
SSC (three washes for 10 minutes each), the cells were put into a pH
9.5 solution (0.1 mol/L Tris, 0.1 mol/L Nacl, 50 mmol/L MgCI2)
for color development with nitroblue tetrazolium (BRL, Gaithers-
burg, MD; 1:230 dilution) and bromochloroindolyl phosphate (BRL,
Gaithersburg, MD;1:300 dilution; developed 20 to 30 minutes).
Isotopic detection was by standard autoradiographic technique;
development was for 3 to 5 days.
RESULTS AND DISCUSSION
In this work we describe the application of in situ hybrid-
ization followed by enzymatic, nonisotopic detection’’6 to
the detection of HIV in a variety of cellular samples. Since
the report of Harper et al,9 it was apparent that the applica-
tion of the approach to HIV detection in clinical samples
required that it be sensitive, convenient, and yet permit a
signal to be evident in an extremely rare infected cell with no
background contributed by negative cells. A progressive
approach to the improvement of methodologies for rapid in
situ hybridization and detection was used. Initial experi-
ments used the producer lines of HIV (CEM or H9) in which
a majority of cells are highly positive to optimize protocol
conditions. For instance, conditions that provided optimal
retention of cells on slides were monitored by microscopy.
Fixation of the cells, treatments prior to probe application,
Fig 2. Detection of serially
diluted infected cells: in situ
hybridization versus dot blot or
immunofluorescence. CEM
cells chronically infected with
HIV were serially diluted 1:1
with uninfected CEM cells. and
aliquots were taken for micros-
copy. Methods of detection
used an indirect immufluores-
cence assay and in situ hybrid-
ization. In addition. dot blots
were made from RNA isolated
from aliquots of the same cells.
(A) Dilution curve (0-0): per-
cent infected cells (average of
10 fields). (0-0) Identical sam-
pies measured by immunofluo-
rescence. (X-X) The expected
percent of infected cells deter-
mined by calculation at each
dilution. Since the undiluted
sample contained 7% positive
cells. as determined by in situ
hybridization. this provided the
numerator in the serial dilu-
tions. (B) Samples in (A) taken
for dot-blot analysis.
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Fig 3. Kinetics of infection of normal T lymphocytes: Detec-
tion of infected cells by in situ hybridization of antigen capture.
Normal T lymphocytes were cultured in vitro for 3 days with IL-2
and PHA and than were infected with HIV-1 at low multiplicity of
infection (MOl). At daily intervals. including just after exposure to
the virus (day 0). cell samples were taken for in situ hybridization.
Three methods of in situ hybridization were used: isotopically
labeled probe (open squares). nonisotopically labeled probe (open
circles), and conjugated oligonucleotides (-). In addition. p24
was measured in the supernatant of the culture using an ELISA
method (open triangles) (Dupont first-generation kit). Control.
uninfected cells were processed at days 0. 1 . and 3 for the ELISA
assay for p24 (x---x). For the in situ hybridization. the results were
0 cells positive on day 0 and day 3.
and hybridization conditions, all of which influence probe
penetration” and accessibility to the target molecules, were
monitored by isotopic detection using 32p-labeled probe
followed by scintillation counting or detection nonisotopical-
ly. Finally nonisotopic detection was evaluated by variation
in chromogen development time or conditions of streptavi-
din-alkaline phosphatase incubation and washing. After
color development, quantitative data were obtained by
counting the positive cells under the microscope and express-
ing them as a percent of total cells. Once the protocols for
detection of HIV were established, comparison of in situ
hybridization with conventional methods of virus detection
such as RNA dot blot’7 and antigen capture methods’8 was
possible. By providing information as to numbers of cells
infected in situ, hybridization provides a means to evaluate
sensitivity, where we have defined sensitivity as the ability to
detect the rare cell. We evaluated this form of sensitivity by a
mixing experiment in which positive cells were diluted (to
less than one in i05 cells). Virus-positive cells were serially
diluted by uninfected cells and the percent positive cells at
each dilution determined by in situ hybridization. Aliquots
were also collected for dot-blot filter hybridization or the
indirect immunofluorescence. Approximately 7% of the cells
in the initial cell culture were positive (I in 14 cells), and
these positive cells could be accurately detected by noniso-
topic in situ hybridization when diluted to one infected cell
per 14,000 (Fig 2A). The false-positive rate was determined
on an uninfected population ofcells and was found to be zero
(no false positives seen in 100,000 cells). Because of the
visual requirements for characterizing a cell as positive (the
cell must be completely colored, indicating significant
amounts of viral RNA in the cytoplasm), the possibility of a
cell being a false positive is negligible. In several million
uninfected cells viewed over many months, we have never
seen a cell that we would characterize as positive. With
background levels this low, any signal is significant, and a
single positive cell represents sufficient signal to score a
sample as positive. This does not mean that samples are
negative if no cell is seen, since a low level of positive cells
may result in sampling variations that eliminate positive
cells. A single positive cell could be detected with confidence
in 50,000 negative cells in many of our samples.
On equivalent samples it was found that the limit of
sensitivity of dot-blot filter hybridization of cellular DNA
was equivalent to one infected cell per 900 (Fig 2B). The
sensitivity of indirect immunofluorescence was limited due to
the higher magnification required by epifluorescence and the
tendency to identify weakly fluorescent cells as false positive.
Hence, detection of infected cells by immunofluorescence
was also accurate in our hands to only about one infected cell
per 1,000.
Another model to assess comparative sensitivity is to
follow the infection of a culture with time where the amount
of viral nucleic acids per cell is increasing, eventually to as
many as tens of thousands of copies of HIV RNA per cell.’
Hence the increase in the number of detectable cells in a
population should represent the increase in viral nucleic acid
per cell as well as an increase in infected cells. Normal
PHA-activated I lymphocytes were infected with HIV
(HTLV-III B) and sampled at daily intervals for 1 week for
HIV detection by in situ hybridization or p24 antigen
capture by ELISA assay (Dupont, Wilmington, DE). In situ
hybridization was done using isotopically labeled probes
detected by autoradiography, biotinylated probes detected
by streptavidin and alkaline phosphatase, and oligonucleo-
tide probes conjugated to alkaline phosphatase directly
(SNAP probes) in a system where fewer copies of HIV per
cell are expressed when compared with producer cell lines.
Both the isotopic and nonisotopic detection of in situ hybrids
using the nick-translated genomic probe were of comparable
sensitivity (Fig 3). The mixture of three different enzyme-
linked oligonucleotides detected, on the average, 25% of the
cells detected using nick-translated probes, and only after an
overnight exposure to the chromagen. We have recently
tested a mixture of 20 enzyme-linked oligonucleotides
(kindly provided by MBI DuPont, Billerica, MA) and found
that the time required for sufficient color development to
detect the positive cells was decreased approximately propor-
tional to the increase in the mixture complexity.
The antigen capture ELISA test was used on the same
samples as in situ hybridization. It was found to be the less
sensitive method as a result of background levels (about 5
pg/mL). Since results from both methods were determined
on equivalent samples, it is possible from Fig 3 to determine
how many positive cells (defined by in situ hybridization) are
required for a positive determination by antigen capture
ELISA assay. We used 40 pg/mL as a confident positive
determination. This level of p24 expression would correspond
to approximately I positive cell per 2500 negative cells. A
lower limit of detection (10 pg/mL) would correspond to
approximately I cell positive per 1 1000 (this value may be
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more compatible with the more sensitive tests now available
from Abbott or DuPont). The background level for in situ
hybridization in this experiment was not detectable (less
than I cell per 100,000 uninfected cells). From these consid-
erations there is an order of magnitude improvement in
sensitivity in detecting cells actively undergoing viral replica-
tion when using in situ hybridization relative to the best
available p24 antigen-capture tests. It should be emphasized
that these tests measure different parameters of infection.
Antigen is detected in the supernatant of the cell cultures,
presumably as a result of lytic infection. These cells would
not be detected by in situ hybridization. Conversely, cells
undergoing viral replication or expression would be detected
by in situ hybridization but not necessarily by antigen
capture. The direct measurement of virus-positive cells
therefore becomes less comparable with the ELISA as
antigen accumulates in the media with increasing time in
culture. Therefore these two approaches should be seen as
providing complementary information.
APPLICATION TO CLINICAL SAMPLES
If the in situ hybridization approach is to become useful
clinically, it must be able to detect the rare virus-positive
cells from infected individuals.9 To determine the ability of
nonisotopic in situ hybridization to detect HIV in the blood
of WV-infected patients, we hybridized patient mononu-
clear cells after coculture with normal, stimulated, human T
lymphocytes and also performed direct hybridization of
patient mononuclear cells without coculture. As in the previ-
ous experiment, we compared all samples with results of the
p24 antigen-capture assay. Two different HIV-seropositive
patient populations were studied: one population consists of
hemophiliacs who are seropositive but asymptomatic, the
other of infants of seropositive mothers. Results are shown in
Table 1 . In situ hybridization detected virus-positive cells in
53% to 54% of both groups during a 3-week coculture with
normal, stimulated T lymphocytes. The p24 antigen-capture
ELISA test detected 24% to 33% of these samples as positive,
all of which agreed with the in situ hybridization results.
Repeated samplings gave similar results. While in situ
hybridization can detect positive cells with shorter times of
culture,’#{176} improvements in both viral culture as well as the
p24 ELISA are also expected to decrease the time needed for
coculture. The isolation of HIV from 98% of HIV seroposi-
tive hemophiliacs using an improved coculture technique
with a larger inoculum (10 x 106) of patient mononuclear
cells has been recently reported.#{176} Furthermore, both Dupont
and Abbott have produced more sensitive p24 detection that
allows decreased culture time. Preliminary comparisons on
similar samples indicate that these improvements increase
the percent of samples scored as positive. As described
previously, in situ hybridization continues to provide quanti-
Fig 4. Examples of detection of viral nucleic acids in positive cells using in situ hybridization. (A) Cells from a normal lymphocyte
culture were infected in vitro with HIV-1 and cultured for 7 days. At this point 1 6% of the cells were positive and were clearly
distinguishable from the uninfected cells. (This constitutes a positive control slide used in conjunction with all our patient detections.) (B)
Positive cells from a seropositive individual after a 7-day coculture with normal lymphocytes. Positive cells were 0.1 % of total cells. (C)
Direct detection of positive cells from patient similar to (B). Positive cells were 0.01 % of total cells. (Note that phase microscopy increases
the contrast of negative cells.)
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tative cellular information complementary to these other
techniques.
The ability of in situ hybridization to detect rare, positive
cells makes it immediately applicable to patient peripheral-
blood lymphocytes. Cells from the same adult patient popu-
lation investigated with coculture above were tested directly
without coculture. Approximately two thirds of the number
of patients detected after coculture were detected positive
without use ofcoculture (34%). The number of virus-positive
cells detected in these patients varied between I cell to 10
cells per well (average 50,000 cells/well). The antigen-
capture assay was positive on 1 1% of these patients’ serum.
The CD4-positive cells of these patients were also assessed,
but no obvious correlation was found between CD4 lympho-
cytes and number of viral-infected circulating mononuclear
cells. Figure 4 shows representative, nonisotopic detection of
HIV nucleic acids in patient samples following coculture and
by direct detection using freshly isolated mononuclear cells.
Peripheral blood monocytes, splenic mononuclear cells,
bone marrow, and cells in culture infected by a sample of
cerebrospinal fluid (CSF) were screened in a preliminary
evaluation of direct testing of other cell types. One seroposi-
tive patient was found to have a single infected cell in a direct
preparation of spleen cells. Coculture of this patient’s blood
mononuclear cells produced a culture with 100 infected cells
per iO cells by day 14 of culture, increasing the confidence
of the detection considerably. Stimulated T cells inoculated
with CSF from a HIV-seropositive individual gave large
numbers of virus-infected cells after 7 days. Several bone
marrow samples were also investigated (isotopically); and
positive cells were found in these patient samples as well, as
were positive cells found in monocyte preparations isolated
and cultured from seropositive donors. It is presumed that
the in situ approach will also prove important for evaluation
of cytologic aspects of the viral infection within tissue
sections obtained by biopsy or autopsy.8’9’2’ While the work
just described is currently anecdotal, it serves to illustrate
further applications for this methodology.
Further increases in sensitivity and convenience will
1. Centers for Disease Control: Quarterly report to the Domestic
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AIDS-United States. MMWR 37:551, 1988
2. US Public Health Service: Coolfont Report: A PHS plan for
prevention and control of AIDS and the AIDS virus. Public Health
Rep 101:34!, 1986
3. Fauci AS: The human immunodeficiency virus: Infectivity and
mechanisms of pathogenesis. Science 239:617, 1988
4. Ward JW, Holmberg SD, Allen JR. Cohn DL, Critchley SE,
Kleinman SH, Lenes BA, Ravenholt 0, Davis JR. Quinn MG, Jaffe
H: Transmission of human immunodeficiency virus (HIV) by blood
transfusions screened as negative for HIV antibody. N EngI J Med
318:473, 1988
5. Scott GB, Buck BE, Letterman JG, Bloom FL, Parks WP:
Acquired immunodeficiency syndrome in infants. N Engl J Med
310:76, 1984
6. Mayer KH, Stoddard AM, McCusker J, Ayotte D, Ferriani R,
Groopman JE: Human T-lymphotropic virus type III in high-risk,
antibody-negative homosexual men. Ann Intern Med 104:194, 1986
improve nonisotopic in situ hybridization; for instance, work
in progress using a protocol developed for fluorescent detec-
tion of a single copy of viral DNA22 can detect a single copy
of integrated HIV DNA. As an alternative or complement to
other means of examination of patient samples such as dot
blot,’ antigen capture,’8 or polymerase chain reaction
(PCR),2325 there are some immediate applications of the
approach described in this work. One of the major contribu-
tions of in situ hybridization is the single-cell nature of the
data, which allows a quantitative assessment of absolute
numbers of cells containing viral nucleic acid. This allows a
direct evaluation of viral load in the patient and can be used
to test the effects of therapeutic drugs. If some patients are
found to contain significant numbers of circulating infected
lymphocytes, their response to therapy could be monitored
using this approach (in vitro or in vivo). Second, the
approach can be used, as shown above, to detect virus-
positive cells in infants ofseropositive mothers, where mater-
nal antibodies may confuse the diagnosis; or in seronegative
individuals to confirm suspected infection.26 Third, it pro-
vides a rapid, quantitative, and convenient complement to
reverse transcriptase or p24 assays in conjunction with virus
culture or serves as an alternative to culture in individuals
with detectable, circulating infected cells. The time required
to complete the assay directly on patient lymphocytes is less
than I day and could be decreased considerably. Finally, it
requires no specialized equipment other than a microscope,
nor does it require specialized training.
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